En undersøgelse af CX11-tabletter til patienter med type 2-diabetes
Et multicenter, randomiseret, dobbeltblindt, placebokontrolleret dosisfindingsstudie af CX11-tabletter hos patienter med type 2-diabetes mellitus
This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days.
The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug.
After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35205-1605
- Central Research Associates - Flourish - PPDS
-
Birmingham, Alabama, Forenede Stater, 35211-1320
- AES - DRS - Synexus Clinical Research US, Inc. - Birmingham
-
Huntsville, Alabama, Forenede Stater, 35802-2569
- AES - DRS - Optimal Research Alabama - Huntsville
-
-
California
-
Cerritos, California, Forenede Stater, 90703
- Core Healthcare Group
-
Long Beach, California, Forenede Stater, 90815-2521
- Ark Clinical Research - Long Beach
-
Walnut Creek, California, Forenede Stater, 94598-3343
- Flourish Research - Walnut Creek - PPDS
-
-
Florida
-
Melbourne, Florida, Forenede Stater, 32934-8172
- AES - DRS - Optimal Research Florida - Melbourne
-
Tampa, Florida, Forenede Stater, 33606-3571
- Tampa General Hospital
-
Winter Park, Florida, Forenede Stater, 32789-1857
- Conquest Research LLC - Winter Park
-
-
Georgia
-
Albany, Georgia, Forenede Stater, 31707-0205
- Privia Medical Group Georgia, LLC - Albany - Javara - PPDS
-
Fayetteville, Georgia, Forenede Stater, 30214
- Javara Inc. - Fayetteville
-
Savannah, Georgia, Forenede Stater, 31406-3928
- Privia Medical Group Georgia, LLC - Savannah - Javara - PPDS
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60602-3960
- AES - DRS - Synexus Clinical Research US, Inc. - Chicago
-
-
Indiana
-
Evansville, Indiana, Forenede Stater, 47714-7513
- AES - DRS - Synexus Clinical Research US, Inc. - Evansville
-
-
Maryland
-
Silver Spring, Maryland, Forenede Stater, 20901-1586
- Privia Medical Group, LLC - Kelly's Collaborative Care - Javara - PPDS
-
-
Michigan
-
Pontiac, Michigan, Forenede Stater, 48341
- Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS
-
-
Minnesota
-
Edina, Minnesota, Forenede Stater, 55435-4305
- AES - DRS - Synexus Clinical Research US, Inc. - Edina - Minneapolis
-
Mankato, Minnesota, Forenede Stater, 56001
- Mankato Clinic - East Main Street - Javara - PPDS
-
-
Mississippi
-
Ridgeland, Mississippi, Forenede Stater, 39157
- Sky Integrative Medical Center
-
-
New Jersey
-
Berlin, New Jersey, Forenede Stater, 08009
- Hassman Research Institute - Berlin - CenExel - PPDS
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87102-2619
- Albuquerque Clinical Trials Inc
-
-
New York
-
Brooklyn, New York, Forenede Stater, 11226
- Brooklyn Clinical Research
-
-
North Carolina
-
Raleigh, North Carolina, Forenede Stater, 27612-8106
- M3 Wake Research, Inc - M3 WR
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390-7202
- University of Texas Southwestern Medical Center
-
Dallas, Texas, Forenede Stater, 75246
- M3 Wake Research - Dallas
-
Mesquite, Texas, Forenede Stater, 751497
- SMS Clinical Research, LLC - 400 W. Kearney St
-
San Antonio, Texas, Forenede Stater, 78229-3539
- Flourish Research - San Antonio - PPDS
-
San Antonio, Texas, Forenede Stater, 78229-3272
- AES - DRS - Synexus Clinical Research US, Inc. - San Antonio
-
Stephenville, Texas, Forenede Stater, 76401-1860
- Privia Medical Group- North Texas - Stephenville - Javara - PPDS
-
-
Virginia
-
Vienna, Virginia, Forenede Stater, 22182
- Conquest Research - Arlington
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polen, 60-702
- AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Poznaniu
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85 001
- Centrum Medyczne Pratia Bydgoszcz - PPDS
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 31-261
- Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne
-
Krakow, Lesser Poland Voivodeship, Polen, 31-501
- FutureMeds - Krakow - PPDS
-
Tarnów, Lesser Poland Voivodeship, Polen, 33-100
- METABOLICA Sp. z o.o
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Polen, 50-381
- AES - DRS - Synexus Polska Sp. z o.o. Oddzial we Wroclawiu
-
-
Lódzkie
-
Lodz, Lódzkie, Polen, 90-127
- AES - DRS - Synexus Polska Sp. Z o.o. Oddzial w Lodzi
-
Lodz, Lódzkie, Polen, 91-363
- FutureMeds - Lodz - PPDS
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 02-672
- AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie
-
Warsaw, Masovian Voivodeship, Polen, 02-677
- ETG Warszawa - PPDS
-
Warsaw, Masovian Voivodeship, Polen, 00-215
- FutureMeds - Warszawa Centrum - PPDS
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polen, 80-382
- AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdansku
-
Gdynia, Pomeranian Voivodeship, Polen, 81-537
- AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdyni
-
-
Silesian Voivodeship
-
Częstochowa, Silesian Voivodeship, Polen, 42-202
- AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Czestochowie
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
Participants who meet all of the following criteria will be eligible to participate in this study:
- Adults aged 18 to 75.
- Diagnosis of type 2 diabetes for at least 6 months.
- HbA1c between 7.0% and 10.5%.
- Body mass index (BMI) between 23 and 50 kg/m².
- Body weight stable for the past 3 months before joining.
- Stable dose of metformin (≥1000 mg/day), with or without SGLT2i, for ≥3 months.
- Women of childbearing potential (WOCBP): highly effective contraception ≥6 months prior to screening, throughout study, and 90 days post-last dose; negative pregnancy test within 24 hrs of first dose; no intent to donate sperm/ova
- Agrees to avoid grapefruit/grapefruit products
Exclusion Criteria
Participants who meet any of the following criteria will be excluded from this study:
-
Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids).
-
Type 1 diabetes or a history of diabetic ketoacidosis.
-
Use of any GLP-1 receptor agonist within the past 6 months, or any prior exposure to CX11.
-
Use of insulin to control blood sugar within the past 12 months.
-
More than one episode of severe low blood sugar, with awareness of hypoglycemia symptoms.
-
Cardiovascular or cerebrovascular conditions within the past 6 months:
- Heart attack, coronary angioplasty, or bypass surgery (diagnostic angiography allowed).
- Valvular heart disease or prior heart valve repair surgery.
- Unstable angina.
- Transient ischemic attack (TIA) or stroke.
- Decompensated heart failure (NYHA Class III or IV).
- ECG abnormalities indicating significant safety risk, such as supraventricular tachycardia, torsades de pointes, second- or third-degree AV block, myocardial infarction, QTcF > 450 ms in males or > 470 ms in females, PR interval > 220 ms.
- Poorly controlled hypertension at screening: systolic ≥ 180 mmHg or diastolic ≥ 100 mmHg.
-
Pancreatic or gallbladder conditions:
- Acute or chronic pancreatitis.
- Symptomatic gallbladder disease (previous cholecystectomy is allowed).
- Pancreatic injury or risk factors that increase pancreatitis risk.
-
Thyroid conditions:
- Poorly controlled abnormal thyroid function on a stable dose before screening.
- Clinically significant abnormal thyroid test results at screening.
- Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type 2A or 2B.
-
Cancer history:
- Malignancy within the past 5 years, regardless of recurrence or metastasis. Exceptions: localized basal cell skin cancer, low-risk prostate cancer, cervical carcinoma in situ, or high-grade prostatic intraepithelial neoplasia.
-
Gastrointestinal conditions or treatments that may affect drug absorption:
- Abnormal gastric emptying (e.g., gastric outlet obstruction).
- Severe chronic gastrointestinal disease, including active ulcer within 6 months.
- Crohn's disease, ulcerative colitis, or other inflammatory bowel diseases.
- Prior gastrointestinal surgery (except polypectomy and appendectomy).
- Long-term use of drugs that directly affect gastrointestinal motility (e.g., mosapride, cisapride).
-
Liver disease:
- Active liver disease other than nonalcoholic fatty liver.
- Chronic active hepatitis B or C.
- Primary biliary cirrhosis.
-
Eye disease:
- Uncontrolled or potentially unstable diabetic retinopathy or maculopathy.
-
Abnormal lab results at screening:
- eGFR < 60 mL/min/1.73 m² (CKD-EPI).
- ALT or AST > 2.5 × upper limit of normal (ULN).
- Total bilirubin > 1.5 × ULN (except known Gilbert's syndrome).
- Serum amylase or lipase > 1.5 × ULN.
- Fasting triglycerides > 5.7 mmol/L.
- TSH > 1.5 × ULN or < 1.0 × LLN.
- Calcitonin ≥ 20 ng/L.
- Hemoglobin < 110 g/L (male) or < 100 g/L (female).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Placebo komparator: Placebo gruppe
|
Matching placebo tablets administered orally once daily (QD) |
|
Eksperimentel: 120 mg gruppe
|
CX11 tablets administered orally once daily (QD)
Andre navne:
|
|
Eksperimentel: 160 mg gruppe
|
CX11 tablets administered orally once daily (QD)
Andre navne:
|
|
Eksperimentel: 40 mg-gruppe
|
CX11 tablets administered orally once daily (QD)
Andre navne:
|
|
Eksperimentel: 80 mg-gruppe
|
CX11 tablets administered orally once daily (QD)
Andre navne:
|
|
Eksperimentel: 200 mg-gruppen
|
CX11 tablets administered orally once daily (QD)
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring i glykosyleret hæmoglobin, type A1C (HbA1c) fra baseline
Tidsramme: Ved uge 24
|
Ved uge 24
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Andel af deltagere, der opnår HbA1c < 7,0%
Tidsramme: Ved uge 24
|
Ved uge 24
|
|
Andel af deltagere, der opnår HbA1c ≤ 6,5%
Tidsramme: Ved uge 24
|
Ved uge 24
|
|
Ændring fra udgangspunktet i Tid i Målområde (TIR) målt med Kontinuerlig Glucosemonitorering (CGM)
Tidsramme: Til uge 24
|
Til uge 24
|
|
Ændring fra baseline i fastende plasmaglukose (FPG)
Tidsramme: Til uge 24
|
Til uge 24
|
|
Ændring i kropsvægt fra udgangspunktet
Tidsramme: Til uge 24
|
Til uge 24
|
|
Procentvis ændring i kropsvægt fra baseline
Tidsramme: Til uge 24
|
Til uge 24
|
|
Andel af deltagere, der opnår et vægttab ≥ 5%
Tidsramme: Ved uge 24
|
Ved uge 24
|
|
Andel af deltagere, der opnår et vægttab ≥ 10%
Tidsramme: I uge 24
|
I uge 24
|
|
Ændring i systolisk blodtryk (SBP) fra baseline
Tidsramme: Til uge 24
|
Til uge 24
|
|
Ændring i diastolisk blodtryk (DBP) fra udgangspunktet
Tidsramme: Til uge 24
|
Til uge 24
|
|
Antal niveau 2 hypoglykæmiske episoder (glukose <54 mg/dL)
Tidsramme: Til uge 24
|
Til uge 24
|
|
Antal svære hypoglykæmiske episoder
Tidsramme: Til uge 24
|
Til uge 24
|
|
Antallet af behandlingsrelaterede bivirkninger (TEAEs)
Tidsramme: Studiets varighed, cirka 26 uger
|
Studiets varighed, cirka 26 uger
|
|
Antal AEs af særlig interesse (AESIs)
Tidsramme: Studiets varighed, cirka 26 uger
|
Studiets varighed, cirka 26 uger
|
|
Plasmakoncentrationer af lægemidlet ved hvert specificerede prøvetagningstidspunkt
Tidsramme: I uge 2, 4, 6, 8, 12, 16, 22 og 24
|
I uge 2, 4, 6, 8, 12, 16, 22 og 24
|
|
Gennemsnitlig plasmakoncentration af lægemidlet ved hver angivne prøvetagningstidspunkt
Tidsramme: Ved uge 2, 4, 6, 8, 12, 16, 22 og 24
|
Ved uge 2, 4, 6, 8, 12, 16, 22 og 24
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- Hypoglykæmi
- Kontinuerlig glukoseovervågning
- Type 2 diabetes mellitus
- Blodsukker
- HbA1C
- Procentvis ændring i HbA1C
- Ændring i fastende plasmaglukose
- Ændring i kropsvægt
- Vægttab
- Hypoglykæmiske episoder
- Health Survey Short Form-36
- Spoergeskema om tilfredshed med diabetesbehandling
- Columbia-selvmordsalvorlighedsskalaen
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CX11202
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .